[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know",
    "summary": "Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=94547d960cc9e43159643399ab73e25cc13b240f8fb5449c0e6cf38e888c7f09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736549422,
      "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know",
      "id": 132421529,
      "image": "https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=94547d960cc9e43159643399ab73e25cc13b240f8fb5449c0e6cf38e888c7f09"
    }
  },
  {
    "ts": null,
    "headline": "INCY vs. VRTX: Which Stock Is the Better Value Option?",
    "summary": "INCY vs. VRTX: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=b9a53d8f404b379671bb489460cd241eb67493587ea62323d7d571e00f74f722",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736527208,
      "headline": "INCY vs. VRTX: Which Stock Is the Better Value Option?",
      "id": 132368179,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "INCY vs. VRTX: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=b9a53d8f404b379671bb489460cd241eb67493587ea62323d7d571e00f74f722"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing, higher-beta growth companies, the strategy underperformed its benchmark the Russell Mid […]",
    "url": "https://finnhub.io/api/news?id=3d394a7d9e03689e05c2f8ba0ab7643702fd0451347acb42a52b5940f530c46e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736516533,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials",
      "id": 132365511,
      "image": "https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing, higher-beta growth companies, the strategy underperformed its benchmark the Russell Mid […]",
      "url": "https://finnhub.io/api/news?id=3d394a7d9e03689e05c2f8ba0ab7643702fd0451347acb42a52b5940f530c46e"
    }
  },
  {
    "ts": null,
    "headline": "Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore",
    "summary": "BOSTON & SHANGHAI & CAMBRIDGE, Mass., January 10, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and",
    "url": "https://finnhub.io/api/news?id=a8e283b1a922fb3eae8d500dc5ca6e7031c5af5b13984da9216b7f2662f27a93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736512200,
      "headline": "Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore",
      "id": 132365514,
      "image": "https://media.zenfs.com/en/business-wire.com/e45bfeaed8099e1bf7234c6bbbb395fd",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON & SHANGHAI & CAMBRIDGE, Mass., January 10, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and",
      "url": "https://finnhub.io/api/news?id=a8e283b1a922fb3eae8d500dc5ca6e7031c5af5b13984da9216b7f2662f27a93"
    }
  },
  {
    "ts": null,
    "headline": "Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore",
    "summary": "SHANGHAI & CAMBRIDGE, Mass. & BOSTON, January 10, 2025--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and",
    "url": "https://finnhub.io/api/news?id=58248d5a8d38254809e61aa72ce68346cc0be48dfbaeab4f8493d416aa115bba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736512200,
      "headline": "Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore",
      "id": 132365512,
      "image": "https://media.zenfs.com/en/business-wire.com/43d45085c716710adc7ef32df488f446",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "SHANGHAI & CAMBRIDGE, Mass. & BOSTON, January 10, 2025--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and",
      "url": "https://finnhub.io/api/news?id=58248d5a8d38254809e61aa72ce68346cc0be48dfbaeab4f8493d416aa115bba"
    }
  },
  {
    "ts": null,
    "headline": "An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued",
    "summary": "Key Insights Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to Equity Vertex...",
    "url": "https://finnhub.io/api/news?id=e1ae84aefa14a29b05cbeec4e35a198d2081e0a784329b52b5ce9b76a205e1b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736506824,
      "headline": "An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued",
      "id": 132365515,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Key Insights Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to Equity Vertex...",
      "url": "https://finnhub.io/api/news?id=e1ae84aefa14a29b05cbeec4e35a198d2081e0a784329b52b5ce9b76a205e1b9"
    }
  }
]